JP2017500057A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017500057A5 JP2017500057A5 JP2016553248A JP2016553248A JP2017500057A5 JP 2017500057 A5 JP2017500057 A5 JP 2017500057A5 JP 2016553248 A JP2016553248 A JP 2016553248A JP 2016553248 A JP2016553248 A JP 2016553248A JP 2017500057 A5 JP2017500057 A5 JP 2017500057A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- set forth
- sequence set
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361901310P | 2013-11-07 | 2013-11-07 | |
| US61/901,310 | 2013-11-07 | ||
| US201462037875P | 2014-08-15 | 2014-08-15 | |
| US62/037,875 | 2014-08-15 | ||
| PCT/US2014/064621 WO2015070061A1 (en) | 2013-11-07 | 2014-11-07 | Anti-wt1/hla bi-specific antibody |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017500057A JP2017500057A (ja) | 2017-01-05 |
| JP2017500057A5 true JP2017500057A5 (enExample) | 2018-05-10 |
| JP6553069B2 JP6553069B2 (ja) | 2019-07-31 |
Family
ID=51987482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016553248A Expired - Fee Related JP6553069B2 (ja) | 2013-11-07 | 2014-11-07 | 抗ｗｔ１／ｈｌａ二重特異性抗体 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP3066130B1 (enExample) |
| JP (1) | JP6553069B2 (enExample) |
| CN (1) | CN106414500B (enExample) |
| ES (1) | ES2742224T3 (enExample) |
| WO (1) | WO2015070061A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| JP6862435B2 (ja) * | 2015-10-09 | 2021-04-21 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 抗ｗｔ１／ｈｌａ特異的抗体 |
| CN116059316A (zh) | 2015-10-23 | 2023-05-05 | 优瑞科生物技术公司 | 抗体/t细胞受体嵌合构建体及其用途 |
| WO2017124001A2 (en) * | 2016-01-14 | 2017-07-20 | Memorial Sloan-Kettering Cancer Center | T cell receptor-like antibodies specific for foxp3-derived peptides |
| DK3579848T3 (da) | 2017-02-08 | 2025-01-20 | Dragonfly Therapeutics Inc | Multispecifikke bindende proteiner til aktivering af naturlige dræberceller og terapeutiske anvendelser heraf til behandling af kræft |
| KR20240060739A (ko) | 2017-02-20 | 2024-05-08 | 드래곤플라이 쎄라퓨틱스, 인크. | Her2, nkg2d 및 cd16에 결합하는 단백질 |
| AU2018258045B2 (en) | 2017-04-26 | 2024-02-29 | Eureka Therapeutics, Inc. | Chimeric antibody/T-cell receptor constructs and uses thereof |
| CA3068634A1 (en) | 2017-06-30 | 2019-01-03 | Memorial Sloan Kettering Cancer Center | Compositions and methods for adoptive cell therapy for cancer |
| JP7072792B2 (ja) * | 2017-12-11 | 2022-05-23 | 国立大学法人神戸大学 | 二重特異性抗体 |
| BR112020011469A2 (pt) | 2017-12-21 | 2020-11-24 | F. Hoffmann-La Roche Ag | anticorpos, molécula de ligação ao antígeno biespecífica, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, uso do anticorpo, método de tratamento de uma doença e invenção |
| SG11202007579TA (en) | 2018-02-08 | 2020-09-29 | Dragonfly Therapeutics Inc | Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells |
| SG11202007482WA (en) | 2018-02-08 | 2020-09-29 | Dragonfly Therapeutics Inc | Antibody variable domains targeting the nkg2d receptor |
| SG11202007697VA (en) | 2018-02-15 | 2020-09-29 | Memorial Sloan Kettering Cancer Center | Foxp3 targeting agent compositions and methods of use for adoptive cell therapy |
| JP7353576B2 (ja) | 2018-02-20 | 2023-10-02 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法 |
| JP2021526365A (ja) * | 2018-05-18 | 2021-10-07 | チルドレンズ ナショナル メディカル センターＣｈｉｌｄｒｅｎ’Ｓ Ｎａｔｉｏｎａｌ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ | 改善された標的化ｔ細胞療法 |
| EP3833385A4 (en) | 2018-08-08 | 2021-12-22 | Dragonfly Therapeutics, Inc. | PROTEINS THAT BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE |
| EP4126044A4 (en) * | 2020-04-02 | 2024-09-04 | The Board Of Regents Of The University Of Texas System | CD5L-BINDING ANTIBODIES AND USES THEREOF |
| CN115836088A (zh) | 2020-05-06 | 2023-03-21 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和clec12a的蛋白质 |
| IL300543A (en) * | 2020-09-24 | 2023-04-01 | Hoffmann La Roche | Prevention or reduction of adverse effects associated with a bispecific T-cell antibody |
| JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
| WO2022187539A1 (en) | 2021-03-03 | 2022-09-09 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen |
| CA3246381A1 (en) * | 2022-03-22 | 2023-09-28 | Morphosys Ag | CD3-SPECIFIC DEIMMUNEIZED ANTIBODIES |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5885573A (en) * | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| ZA200601699B (en) * | 2003-10-16 | 2007-05-30 | Micromet Ag | Multispecific deimmunized CD3-binders |
| JP2009521474A (ja) * | 2005-12-21 | 2009-06-04 | メディミューン，エルエルシー | ＥｐｈＡ２ＢｉＴＥ分子およびその使用 |
| AU2012236068A1 (en) * | 2011-04-01 | 2013-10-17 | Eureka Therapeutics, Inc. | T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2 |
-
2014
- 2014-11-07 ES ES14803300T patent/ES2742224T3/es active Active
- 2014-11-07 WO PCT/US2014/064621 patent/WO2015070061A1/en not_active Ceased
- 2014-11-07 CN CN201480061156.9A patent/CN106414500B/zh not_active Expired - Fee Related
- 2014-11-07 EP EP14803300.4A patent/EP3066130B1/en active Active
- 2014-11-07 JP JP2016553248A patent/JP6553069B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL265541B2 (en) | Bispecific antibodies and compounds containing them for the treatment of cancer | |
| JP2017535257A5 (enExample) | ||
| US20210024635A1 (en) | Anti-wt1/hla-specific antibodies | |
| JP2021527431A5 (enExample) | ||
| JP2021533726A5 (enExample) | ||
| JP2021515565A5 (enExample) | ||
| JP2021516974A5 (enExample) | ||
| JP2021515568A5 (enExample) | ||
| JP2019510733A5 (enExample) | ||
| JP2021515566A5 (enExample) | ||
| JP2021516973A5 (enExample) | ||
| JP2020534250A5 (enExample) | ||
| JP2017524715A5 (enExample) | ||
| JP2021501162A5 (enExample) | ||
| JP2015163068A5 (enExample) | ||
| JP2014522850A5 (enExample) | ||
| RU2016124540A (ru) | Композиции, содержащие анти-сеасам 1 и анти-pd антитела для терапии рака | |
| JP2020508334A5 (enExample) | ||
| JP2020515247A5 (enExample) | ||
| JP2018532383A5 (enExample) | ||
| JP2018512379A5 (enExample) | ||
| RU2016129517A (ru) | Биспецифические антитела к her2 и способы применения | |
| JP2021514973A5 (enExample) | ||
| WO2016191246A3 (en) | T cell receptor-like antibodies specific for a prame peptide | |
| JP2018508483A5 (enExample) |